Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| AIDS Dementia Complex | 19 | 2025 | 116 | 3.550 |
Why?
|
| HIV Infections | 16 | 2025 | 2535 | 1.620 |
Why?
|
| Cognition Disorders | 9 | 2017 | 243 | 1.600 |
Why?
|
| HIV Seropositivity | 8 | 2018 | 196 | 1.090 |
Why?
|
| Receptor, Insulin | 2 | 2015 | 26 | 0.830 |
Why?
|
| HIV-1 | 10 | 2025 | 747 | 0.730 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2023 | 229 | 0.620 |
Why?
|
| Puerto Rico | 10 | 2020 | 1376 | 0.600 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 167 | 0.540 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 246 | 0.520 |
Why?
|
| Neuropsychological Tests | 8 | 2024 | 281 | 0.510 |
Why?
|
| Monocytes | 7 | 2025 | 275 | 0.490 |
Why?
|
| Access to Information | 1 | 2015 | 14 | 0.490 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 51 | 0.460 |
Why?
|
| Humans | 41 | 2025 | 42163 | 0.460 |
Why?
|
| Models, Biological | 1 | 2018 | 711 | 0.450 |
Why?
|
| Cell Movement | 1 | 2018 | 640 | 0.440 |
Why?
|
| Exercise | 1 | 2020 | 674 | 0.430 |
Why?
|
| Adult | 24 | 2025 | 13458 | 0.430 |
Why?
|
| Female | 30 | 2025 | 24018 | 0.410 |
Why?
|
| Macrophages | 5 | 2017 | 515 | 0.400 |
Why?
|
| Insulin Resistance | 1 | 2015 | 199 | 0.390 |
Why?
|
| Apolipoproteins | 1 | 2012 | 22 | 0.390 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 23 | 0.370 |
Why?
|
| DNA, Viral | 1 | 2013 | 323 | 0.370 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 158 | 0.360 |
Why?
|
| Middle Aged | 19 | 2025 | 11819 | 0.350 |
Why?
|
| HIV | 2 | 2013 | 100 | 0.350 |
Why?
|
| Learning | 1 | 2012 | 155 | 0.350 |
Why?
|
| Cognition | 3 | 2024 | 458 | 0.340 |
Why?
|
| Proteomics | 6 | 2017 | 363 | 0.340 |
Why?
|
| Basilar Artery | 1 | 2010 | 10 | 0.330 |
Why?
|
| Puerperal Disorders | 1 | 2010 | 15 | 0.320 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 61 | 0.320 |
Why?
|
| Education, Distance | 1 | 2010 | 46 | 0.310 |
Why?
|
| Thrombosis | 1 | 2010 | 81 | 0.310 |
Why?
|
| Dementia | 1 | 2010 | 155 | 0.290 |
Why?
|
| Research | 1 | 2007 | 177 | 0.240 |
Why?
|
| Protein Array Analysis | 2 | 2004 | 27 | 0.230 |
Why?
|
| Hippocampus | 2 | 2022 | 591 | 0.220 |
Why?
|
| Cohort Studies | 6 | 2024 | 1729 | 0.210 |
Why?
|
| Memory | 3 | 2012 | 175 | 0.210 |
Why?
|
| Neurology | 2 | 2013 | 13 | 0.200 |
Why?
|
| Proteome | 2 | 2017 | 150 | 0.200 |
Why?
|
| Exosomes | 1 | 2025 | 124 | 0.200 |
Why?
|
| Flumazenil | 1 | 2000 | 1 | 0.170 |
Why?
|
| Midazolam | 1 | 2000 | 3 | 0.170 |
Why?
|
| Hypnotics and Sedatives | 1 | 2000 | 27 | 0.170 |
Why?
|
| Smoking | 1 | 2007 | 1019 | 0.170 |
Why?
|
| HIV Antibodies | 1 | 2020 | 24 | 0.170 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 17 | 0.170 |
Why?
|
| Glycopeptides | 1 | 2020 | 14 | 0.170 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 111 | 0.160 |
Why?
|
| Anthropometry | 1 | 2020 | 96 | 0.160 |
Why?
|
| Electroencephalography | 1 | 2000 | 135 | 0.160 |
Why?
|
| Cells, Cultured | 3 | 2018 | 1617 | 0.160 |
Why?
|
| Disease Progression | 3 | 2013 | 661 | 0.150 |
Why?
|
| Longitudinal Studies | 5 | 2013 | 1020 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 3077 | 0.150 |
Why?
|
| Quality of Life | 2 | 2013 | 599 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2015 | 2485 | 0.140 |
Why?
|
| Cerebrospinal Fluid | 2 | 2007 | 20 | 0.140 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2017 | 10 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 280 | 0.120 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 89 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2018 | 467 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2018 | 960 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 1058 | 0.120 |
Why?
|
| Lymphocytes | 2 | 2013 | 124 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2017 | 336 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 28 | 0.110 |
Why?
|
| Viral Load | 4 | 2013 | 344 | 0.110 |
Why?
|
| Public Health | 1 | 2018 | 405 | 0.110 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 7 | 0.110 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2013 | 5 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2013 | 64 | 0.100 |
Why?
|
| 14-3-3 Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Male | 9 | 2024 | 22779 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 456 | 0.100 |
Why?
|
| Epilepsy | 1 | 2013 | 56 | 0.100 |
Why?
|
| Cystatin B | 1 | 2013 | 11 | 0.100 |
Why?
|
| Fatigue | 1 | 2013 | 97 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gene Expression | 2 | 2013 | 692 | 0.100 |
Why?
|
| Cathepsin B | 1 | 2013 | 35 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2013 | 41 | 0.090 |
Why?
|
| Internet | 2 | 2012 | 234 | 0.090 |
Why?
|
| Reaction Time | 1 | 2012 | 151 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 76 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 225 | 0.090 |
Why?
|
| Alleles | 1 | 2012 | 352 | 0.090 |
Why?
|
| Psychometrics | 2 | 2017 | 350 | 0.090 |
Why?
|
| Prevalence | 2 | 2024 | 1597 | 0.080 |
Why?
|
| Pharmacology | 1 | 2010 | 6 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2010 | 5 | 0.080 |
Why?
|
| Allergy and Immunology | 1 | 2010 | 13 | 0.080 |
Why?
|
| Foramen Ovale, Patent | 1 | 2010 | 5 | 0.080 |
Why?
|
| Neurosciences | 1 | 2010 | 33 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2007 | 200 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 727 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 708 | 0.080 |
Why?
|
| Aged | 4 | 2024 | 7982 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2012 | 973 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1266 | 0.080 |
Why?
|
| Mentors | 1 | 2010 | 143 | 0.070 |
Why?
|
| Antioxidants | 2 | 2010 | 439 | 0.070 |
Why?
|
| Health Status | 1 | 2012 | 432 | 0.070 |
Why?
|
| Language | 1 | 2010 | 181 | 0.070 |
Why?
|
| Glutathione Peroxidase | 1 | 2008 | 100 | 0.070 |
Why?
|
| Catalase | 1 | 2008 | 111 | 0.070 |
Why?
|
| Focus Groups | 1 | 2010 | 398 | 0.070 |
Why?
|
| Superoxide Dismutase | 1 | 2008 | 158 | 0.070 |
Why?
|
| Intelligence Tests | 1 | 2007 | 8 | 0.070 |
Why?
|
| ROC Curve | 1 | 2007 | 157 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2007 | 39 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 2803 | 0.070 |
Why?
|
| Hawaii | 1 | 2013 | 2004 | 0.070 |
Why?
|
| Wechsler Scales | 1 | 2006 | 7 | 0.060 |
Why?
|
| Women's Health | 1 | 2007 | 158 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 156 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2025 | 53 | 0.060 |
Why?
|
| Minority Groups | 1 | 2010 | 663 | 0.060 |
Why?
|
| Algorithms | 1 | 2007 | 508 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 683 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2023 | 30 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2007 | 1574 | 0.050 |
Why?
|
| Heroin | 1 | 2002 | 18 | 0.050 |
Why?
|
| Narcotics | 1 | 2002 | 30 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 100 | 0.050 |
Why?
|
| California | 1 | 2024 | 531 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2017 | 574 | 0.050 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2002 | 81 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2017 | 884 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 267 | 0.040 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2020 | 20 | 0.040 |
Why?
|
| Depression | 1 | 2007 | 837 | 0.040 |
Why?
|
| Cricetulus | 1 | 2020 | 82 | 0.040 |
Why?
|
| CHO Cells | 1 | 2020 | 123 | 0.040 |
Why?
|
| Glycosylation | 1 | 2020 | 111 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cricetinae | 1 | 2020 | 241 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 118 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 522 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 295 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2007 | 78 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2024 | 705 | 0.030 |
Why?
|
| Microwaves | 1 | 2017 | 27 | 0.030 |
Why?
|
| Insurance, Major Medical | 1 | 2017 | 5 | 0.030 |
Why?
|
| Magnetics | 1 | 2017 | 43 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 4936 | 0.030 |
Why?
|
| Adolescent | 2 | 2013 | 5950 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 173 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2007 | 279 | 0.030 |
Why?
|
| Calgranulin B | 1 | 2015 | 4 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 169 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 245 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 230 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 95 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2002 | 825 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 1559 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1054 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2013 | 14 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 77 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 107 | 0.030 |
Why?
|
| Ceramides | 1 | 2013 | 43 | 0.030 |
Why?
|
| Hospitalization | 1 | 2017 | 482 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 200 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 34 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 438 | 0.020 |
Why?
|
| Cholesterol | 1 | 2013 | 230 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 411 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 2010 | 12 | 0.020 |
Why?
|
| Peroxiredoxins | 1 | 2010 | 10 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 67 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 57 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 63 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2010 | 36 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 534 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 162 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 167 | 0.020 |
Why?
|
| Complement C3 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 198 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 64 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 74 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 16695 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 238 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 182 | 0.020 |
Why?
|
| Glioma | 1 | 2007 | 92 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 526 | 0.020 |
Why?
|
| Neurons | 2 | 2003 | 1246 | 0.010 |
Why?
|
| Virus Replication | 1 | 2007 | 318 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 3942 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1188 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 774 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 5 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nerve Growth Factors | 1 | 2003 | 34 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 2002 | 36 | 0.010 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 55 | 0.010 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2002 | 52 | 0.010 |
Why?
|
| United States | 1 | 2013 | 5072 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 602 | 0.010 |
Why?
|
| Dopamine | 1 | 2002 | 272 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2598 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 633 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2003 | 475 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 1452 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3701 | 0.010 |
Why?
|